Clinical Trials Integrating Immunotherapy and Radiation for Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology

Volumn 10, Issue 12, 2015, Pages 1685-1693

  Daly, Megan E ^a   Monjazeb, Arta M ^a   Kelly, Karen ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Immunotherapy; Non small cell lung cancer; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOMODULATING AGENT; IPILIMUMAB; MPDL 3280A; NIVOLUMAB; PEMBROLIZUMAB; TECEMOTIDE;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL (TOPIC); HUMAN; IMMUNOMODULATION; METASTASIS; NON SMALL CELL LUNG CANCER; PATIENT SELECTION; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; TUMOR ASSOCIATED LEUKOCYTE; CARCINOMA, NON-SMALL-CELL LUNG; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; PROCEDURES;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS;

EID: 84948084860     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000686     Document Type: Review

References (75)

1. Gail MH. A placebo-controlled randomized double-blind study of adjuvant intrapleural BCG in patients with resected T1N0, T1N1, or T2N0 squamous cell carcinoma, adenocarcinoma, or large cell carcinoma of the lung. LCSG Protocol 771. Chest 1994;106:287S-292S.
2. Roeslin N, Dumont P, Morand G, Wihlm JM, Witz JP. Immunotherapy as an adjuvant to surgery in carcinoma of bronchus. Results in three randomised trials. Eur J Cardiothorac Surg 1989;3:430-435.
3. Bradley JD, Scott CB, Paris KJ, et al. A phase III comparison of radiation therapy with or without recombinant beta-interferon for poor-risk patients with locally advanced non-small-cell lung cancer (RTOG 93-04). Int J Radiat Oncol Biol Phys 2002;52:1173-1179.
4. O'Brien ME, Anderson H, Kaukel E, et al. SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: Phase III results. Ann Oncol 2004;15:906-914.
5. Scagliotti GV, Bironzo P, Vansteenkiste JF. Addressing the unmet need in lung cancer: The potential of immuno-oncology. Cancer Treat Rev 2015;41:465-475.
6. Ramalingam SS, Mazieres J, Planchard D, et al. Phase II study of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced, refractory squamous non-small cell lung cancer: Metastatic non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2014;90:1266-1267.
7. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-2454.
8. http://news.bms.com/press-release/checkmate-017-phase-3-studyopdivo-nivolumab-compared-docetaxel-patients-second-line-s. Accessed February 16, 2015.
9. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123-135.
10. Paz-Ares L, Horn L, Borghaei H, et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). Presented at the American Society for Clinical Oncology, Chicago, IL, 2015.
11. Nivolumab approved for lung cancer. Cancer Discov 5:OF1, 2015.
12. Klug F, Prakash H, Huber PE, et al. Low-dose irradiation programs macrophage differentiation to an iNOS+/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 2013;24:589-602.
13. Wu CY, Yang LH, Yang HY, et al. Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors. Clin Cancer Res 2014;20:644-657.
14. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007;13:1050-1059.
15. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007;13:54-61.
16. Chakraborty M, Abrams SI, Camphausen K, et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003;170:6338-6347.
17. Formenti SC, Demaria S. Systemic effects of local radiotherapy. Lancet Oncol 2009;10:718-726.
18. Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol 2008;180:3132-3139.
19. Obeid M, Panaretakis T, Joza N, et al. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ 2007;14:1848-1850.
20. Ganss R, Ryschich E, Klar E, Arnold B, Hämmerling GJ. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res 2002;62:1462-1470.
21. Matsumura S, Wang B, Kawashima N, et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol 2008;181:3099-3107.
22. Strome SE, Voss S, Wilcox R, et al. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Cancer Res 2002;62:1884-1889.
23. Dovedi SJ, Adlard AL, Lipowska-Bhalla G, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 2014;74:5458-5468.
24. Mole RH. Whole body irradiation; radiobiology or medicine Br J Radiol 1953;26:234-241.
25. Reynders K, Illidge T, Siva S, Chang JY, De Ruysscher D. The abscopal effect of local radiotherapy: Using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev 2015;41:503-510.
26. McCoach CE, Kelly K. Treatment paradigms in advanced non-small-cell lung cancer. Clin Adv Hematol Oncol 2013;11:629-639.
27. Dovedi SJ, Melis MH, Wilkinson RW, et al. Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma. Blood 2013;121:251-259.
28. Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009;15:5379-5388.
29. Lee Y, Auh SL, Wang Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: Changing strategies for cancer treatment. Blood 2009;114:589-595.
30. Schaue D, Ratikan JA, Iwamoto KS, McBride WH. Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys 2012;83:1306-1310.
31. Crittenden M, Kohrt H, Levy R, et al. Current clinical trials testing combinations of immunotherapy and radiation. Semin Radiat Oncol 2015;25:54-64.
32. www.clinicaltrials.gov. Study of combined ionizing radiation and ipilimumab in metastatic non-small cell lung cancer (NSCLC). Accessed April 5, 2015.
33. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 2009;15:7412-7420.
34. www.clinicaltrials.gov. Ipilimumab and stereotactic body radiation therapy (SBRT) in advanced solid tumors. Accessed April 5, 2015.
35. www.clinicaltrials.gov. Radiation therapy and MK-3475 for patients with recurrent/metastatic head and neck cancer, renal cell cancer, urothelial cancer, melanoma, and non-small cell lung cancer. Accessed April 5, 2015.
36. www.clinicaltrials.gov. RADVAX: A stratified phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with advanced and metastatic cancers. Accessed April 5, 2015.
37. Grimaldi AM, Simeone E, Giannarelli D, et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology 2014;3:e28780.
38. www.clinicaltrials.gov MPDL3280A and stereotactic ablative radiotherapy in patients with non-small cell lung cancer. Accessed April 5, 2015.
39. van den Heuvel MM, Verheij M, Boshuizen R, et al. NHS-IL2 combined with radiotherapy: Preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy. J Transl Med 2015;13:32.
40. Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012;30:419-425.
41. Di Giacomo AM, Margolin K. Immune checkpoint blockade in patients with melanoma metastatic to the brain. Semin Oncol 2015;42:459-465.
42. Goldberg S, Gettinger S, Mahajan A, et al. Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases. Presented at the American Society for Clinical Oncology, Chicago, IL, 2015.
43. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial. Lancet Oncol 2012;13:459-465.
44. www.clinicaltrials.gov. Ipilimumab induction in patients with melanoma brain metastases receiving stereotactic radiosurgery. Accessed June 26, 2015.
45. Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015;520:373-377.
46. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990;323:940-945.
47. Sause W, Kolesar P, Taylor S IV, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000;117:358-364.
48. Curran WJ Jr, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: Randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011;103:1452-1460.
49. Fournel P, Robinet G, Thomas P, et al.; Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francąis de Pneumo-Cancérologie. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francąis de Pneumo-Cancérologie NPC 95-01 Study. J Clin Oncol 2005;23:5910-5917.
50. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-2699.
51. Zatloukal P, Petruzelka L, Zemanova M, et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: A randomized study. Lung Cancer 2004;46:87-98.
52. Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): A randomised, two-by-two factorial phase 3 study. Lancet Oncol 2015;16:187-199.
53. Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: A randomized phase II locally advanced multi-modality protocol. J Clin Oncol 2005;23:5883-5891.
54. Vokes EE, Herndon JE 2nd, Kelley MJ, et al.; Cancer and Leukemia Group B. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007;25:1698-1704.
55. Hanna N, Neubauer M, Yiannoutsos C, et al.; Hoosier Oncology Group; US Oncology. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: The Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008;26:5755-5760.
56. Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008;26:2450-2456.
57. Garg S, Gielda BT, Kiel K, et al. Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy. Pract Radiat Oncol 2014;4:342-348.
58. www.seer.cancer.gov SEER stat fact sheets: Lung and bronchus cancer. Accessed April 10, 2015.
59. Kimura H, Yamaguchi Y. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer 1997;80:42-49.
60. Sangha R, Butts C. L-BLP25: A peptide vaccine strategy in non small cell lung cancer. Clin Cancer Res 2007;13(15 Pt 2):s4652-s4654.
61. Palmer M, Parker J, Modi S, et al. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin Lung Cancer 2001;3:49-57; discussion 58.
62. Butts C, Maksymiuk A, Goss G, et al. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): Phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol 2011;137:1337-1342.
63. Butts C, Murray N, Maksymiuk A, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005;23:6674-6681.
64. Butts C, Socinski MA, Mitchell PL, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): A randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15:59-68.
65. Ohyanagi F, Horai T, Sekine I, et al. Safety of BLP25 liposome vaccine (L-BLP25) in Japanese patients with unresectable stage III NSCLC after primary chemoradiotherapy: Preliminary results from a Phase I/II study. Jpn J Clin Oncol 2011;41:718-722.
66. Wu YL, Park K, Soo RA, et al. INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. BMC Cancer 2011;11:430.
67. Merck discontinues clinical development program of tecemotide as a monotherapy in stage III non-small cell lung cancer. http://www. emdgroup.com/emd/media/extNewsDetail.htmlnewsId=8475BA17A3F 51470C1257D50006901B4&newsType=1. Accessed April 5, 2015.
68. www.clinicaltrials.gov. Tecemotide following concurrent chemo-radiotherapy for non-small cell lung cancer (START2). Accessed April 5, 2015.
69. www.clinicaltrials.gov. BLP25 liposome vaccine and bevacizumab after chemotherapy and radiation therapy in treating patients with newly diagnosed stage IIIA or stage IIIB non-small cell lung cancer that cannot be removed by surgery. Accessed April 15, 2015.
70. www.clinicaltrials.gov. A global study to assess the effects of MEDI4736 following concurrent chemoradiation in patients with stage III unresectable non-small cell lung cancer (PACIFIC). Accessed April 5, 2015.
71. http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails. aspxstudy=9909. Phase II study of postoperative adjuvant immunotherapy and radiation in patients with ccompletely resected stage II and stage IIIA non-small cell lung cancer. Accessed April 10, 2015.
72. Baumann P, Nyman J, Hoyer M, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 2009;27:3290-3296.
73. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010;303:1070-1076.
74. Chi A, Liao Z, Nguyen NP, Xu J, Stea B, Komaki R. Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: Clinical implications. Radiother Oncol 2010;94:1-11.
75. Timmerman RD, Choy H, Michalski J, et al. Long-term results of RTOG 0236: A phase II trial of stereotactic body radiation therapy (SBRT) in the treatment of patients with medically inoperable stage I non-small cell lung cancer Int J Radiat Oncol Biol Phys 2014;90